Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Brendon is passionate about translating innovative research discoveries into potential new therapies and has extensive experience leading collaborative multidisciplinary drug discovery programs. Prior to joining MIPS as the Director of MedChem Australia, Brendon was the Chief Scientific Officer of Canthera Discovery, formerly the Cancer Therapeutics CRC (CTx), a leading Australian small molecule drug discovery organisation whose research partners included Monash University, CSIRO, WEHI, Peter MacCallum Cancer Centre, Children’s Cancer Institute and Griffith University.

Brendon has a molecular biology background with research experience in drug discovery, cancer biology, gene regulation and epigenetics. Brendon has contributed to many successfully licensed drug discovery programs across epigenetic, kinase, RNA modulation, and immuno-oncology targets, with two assets currently in active clinical trials.

Brendon was the project leader of the lysine acetyltransferase projects licensed to Pfizer in a deal worth $20M upfront, ~$650M in potential milestone payments, plus royalties. 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Research area keywords

  • Drug discovery
  • Biomedical Research, Multidisciplinary
  • Translational Medical Research
  • Collaborative translation
  • Cancer therapeutics
  • Therapeutic Development